CST changes and VA in nAMD: A review of the evidence

Post-hoc analyses and real-world studies demonstrate the link between central subfoveal thickness fluctuations and visual acuity in neovascular age-related macular degeneration.

Metformin’s potential impact on AMD prevention

Multiple observational studies have shown the potential of the antidiabetic drug in the management of age-related macular degeneration.

Reframing the discussion around geographic atrophy

Understanding the natural disease progression will help us talk to our patients about new and emerging treatments.

Understanding the risk of GA in nAMD

A look at research that sheds new light into the progression of geographic atrophy in neovascular age-related macular degeneration.

Update on mitochondrial stabilizers

Also from the Angiogenesis, Exudation, and Degeneration meeting, emerging treatments for nAMD and MacTel2, and a marker for anti-VEGF success in ROP.

Axitinib implant shows early potential

Interim results from Phase I trial of OTX-TKI, a bioresorbable hydrogel platform using a tyrosine kinase inhibitor.

AAO Report: New insights into ILM tears, trial readouts and more

Five abstracts on gene therapy and role of central subfield thickness in diabetic macular edema, vitreous hemorrhage and retinopathy of prematurity.

Treat and extend: An international view

Three experts from Canada, Switzerland and Israel provide insights into the nuances of adherence, treatment intervals and emerging therapies.

A closer look at emerging drug-delivery platforms

An update on Port Delivery System with ranibizumab, a large-molecule anti-VEGF candidate and subretinal gene therapy to treat neovascular AMD.

Retinal implant platforms moving from uveitis to AMD

Treatments show potential for various posterior-segment diseases based on their success treating noninfectious uveitis.

Using OCT to evaluate fluid in non-neovascular AMD

How optical coherence tomography, OCT angiography and fluorescein angiography can help direct diagnosis and treatment decisions.

Five emerging treatments show mixed results

Uncertainty about PVL for VMT and aflibercept for NPDR, some clarity on PDT, and early promise for stem cells and a bioresorbable implant.

How imaging is advancing management of dry AMD

Emerging modalities and deep learning are helping to expose an old foe in non-neovascular age-related macular degeneration: reticular pseudodrusen.

Imaging biomarkers and precision medicine

Advances in computational power, and machine learning and diagnostic systems are creating new opportunities for understanding disease mechanisms.

Where genetics, diet and drusen size intersect

A close look at research into how diet may reverse the effect of genetic susceptibility in drusen size progression in age-related macular degeneration.

Will biosimilars find their place in retina?

With patents expiring, an approval pending and legislation aimed at easing regulations, more biosimilars could be coming. But are retina specialists ready?

The complement pathway in geographic atrophy explained

Examining the role of complement factors in advanced disease.

The promise of targeting mitochondria in dry AMD

Mitochondrial therapies have shown the potential to improve visual function in patients with dry age-related macular degeneration.

Understanding role of Ang2 in neovascular AMD

Angiopoietin-2 is an increasingly desirable target in age-related macular degeneration. Here’s why, and an assessment of investigative treatments.

Lessons from CANTREAT: fewer visits, BCVA improvement

Level 1 evidence now supports treat-and-extend vs. monthly intervals for anti-VEGF treatment of neovascular age-related macular degeneration.